Publications by authors named "G Buescher"
Current practice in the management of paediatric autoimmune liver disease in Europe.
J Pediatr Gastroenterol Nutr
December 2024
Article Synopsis
- The study examines how paediatric autoimmune liver disease (pAILD) is managed across various European medical centers, revealing significant variation in treatment approaches and drug availability.
- A survey from 36 centers indicated that most treat fewer than 50 children with pAILD, primarily using prednisolone as the first-line treatment, with azathioprine and mycophenolate as common second-line options.
- The availability of appropriate paediatric formulations for these medications is limited across Europe, highlighting the need for collaborative strategies to ensure effective and equitable treatments for affected children.
Article Synopsis
- - The study investigates the role of soluble CD27 (sCD27) and its potential as a biomarker to predict patient responses to immune checkpoint inhibitors (ICIs) in cancer therapy, as many patients do not achieve lasting results with current treatments.
- - Researchers assessed serum and plasma levels of sCD27 across three patient cohorts (totaling 187 individuals) receiving ICI therapy, utilizing immunoassays and investigating both circulating and extracellular vesicle-bound forms of CD27.
- - Results showed that lower levels of sCD27 in patients treated with ICIs were associated with longer progression-free survival and overall survival, suggesting that sCD27 could serve as a valuable predictive biomarker for the effectiveness of ICI treatments.
Introduction: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune-related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune and cholestatic liver disease (AILD) remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- There is limited data on the safety and effectiveness of immunomodulatory drugs for treating autoimmune hepatitis (AIH), even though they are commonly used for other autoimmune conditions.
- A survey of hepatology centers in Europe revealed 25 AIH patients, most of whom received standard AIH treatment before starting unconventional therapies to address other autoimmune diseases.
- At the end of the follow-up period, 13 patients achieved a complete biochemical response, though some experienced relapses or insufficient response, and side effects from treatments were reported.